BACKGROUND: The multicenter, cluster-randomized Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) trial was performed in 18 U.S. adult intensive care units (ICUs). It evaluated the effectiveness of infection control strategies to reduce the transmission of methicillin-resistant Staphylococcus aureus (MRSA) colonization and/or infection. Our study objective was to examine the molecular epidemiology of MRSA and assess the prevalence and risk factors for community acquired (CA)-MRSA genotype nasal carriage at the time of ICU admission. METHODS: Selected MRSA isolates were subjected to molecular typing using pulsed-field gel electrophoresis. RESULTS: Of 5,512 ICU patient admissions in the STAR*ICU trial during the intervention period, 626 (11%) had a nares sample culture result that was positive for MRSA. A total of 210 (34%) of 626 available isolates were selected for molecular typing by weighted random sampling. Of 210 patients, 123 (59%) were male; mean age was 63 years. Molecular typing revealed that 147 isolates (70%) were the USA100 clone, 26 (12%) were USA300, 12 (6%) were USA500, 8 (4%) were USA800, and 17 (8%) were other MRSA genotypes. In a multivariate analysis, patients who were colonized with a CA-MRSA genotype (USA300, USA400, or USA1000) were less likely to have been hospitalized during the previous 12 months (PR [prevalence ratio], 0.39 [95% confidence interval (CI), 0.21-0.73]) and were less likely to be older (PR, 0.97 [95% CI, 0.95-0.98] per year) compared with patients who were colonized with a healthcare-associated (HA)-MRSA genotype. CONCLUSION: CA-MRSA genotypes have emerged as a cause of MRSA nares colonization among patients admitted to adult ICUs in the United States. During the study period (2006), the predominant site of CA-MRSA genotype acquisition appeared to be in the community.
RCT Entities:
BACKGROUND: The multicenter, cluster-randomized Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) trial was performed in 18 U.S. adult intensive care units (ICUs). It evaluated the effectiveness of infection control strategies to reduce the transmission of methicillin-resistant Staphylococcus aureus (MRSA) colonization and/or infection. Our study objective was to examine the molecular epidemiology of MRSA and assess the prevalence and risk factors for community acquired (CA)-MRSA genotype nasal carriage at the time of ICU admission. METHODS: Selected MRSA isolates were subjected to molecular typing using pulsed-field gel electrophoresis. RESULTS: Of 5,512 ICU patient admissions in the STAR*ICU trial during the intervention period, 626 (11%) had a nares sample culture result that was positive for MRSA. A total of 210 (34%) of 626 available isolates were selected for molecular typing by weighted random sampling. Of 210 patients, 123 (59%) were male; mean age was 63 years. Molecular typing revealed that 147 isolates (70%) were the USA100 clone, 26 (12%) were USA300, 12 (6%) were USA500, 8 (4%) were USA800, and 17 (8%) were other MRSA genotypes. In a multivariate analysis, patients who were colonized with a CA-MRSA genotype (USA300, USA400, or USA1000) were less likely to have been hospitalized during the previous 12 months (PR [prevalence ratio], 0.39 [95% confidence interval (CI), 0.21-0.73]) and were less likely to be older (PR, 0.97 [95% CI, 0.95-0.98] per year) compared with patients who were colonized with a healthcare-associated (HA)-MRSA genotype. CONCLUSION: CA-MRSA genotypes have emerged as a cause of MRSA nares colonization among patients admitted to adult ICUs in the United States. During the study period (2006), the predominant site of CA-MRSA genotype acquisition appeared to be in the community.
Authors: X Corbella; M A Domínguez; M Pujol; J Ayats; M Sendra; R Pallares; J Ariza; F Gudiol Journal: Eur J Clin Microbiol Infect Dis Date: 1997-05 Impact factor: 3.267
Authors: W Charles Huskins; Charmaine M Huckabee; Naomi P O'Grady; Patrick Murray; Heather Kopetskie; Louise Zimmer; Mary Ellen Walker; Ronda L Sinkowitz-Cochran; John A Jernigan; Matthew Samore; Dennis Wallace; Donald A Goldmann Journal: N Engl J Med Date: 2011-04-14 Impact factor: 91.245
Authors: Marcus V DA Silva Coimbra; Lenise A Teixeira; Rose L B Ramos; Silvia C Predari; Liliana Castello; Angela Famiglietti; Carlos Vay; Lilian Klan; Agnes M S Figueiredo Journal: J Med Microbiol Date: 2000-02 Impact factor: 2.472
Authors: John J Engemann; Yehuda Carmeli; Sara E Cosgrove; Vance G Fowler; Melissa Z Bronstein; Sharon L Trivette; Jane P Briggs; Daniel J Sexton; Keith S Kaye Journal: Clin Infect Dis Date: 2003-02-07 Impact factor: 9.079
Authors: Sara E Cosgrove; George Sakoulas; Eli N Perencevich; Mitchell J Schwaber; Adolf W Karchmer; Yehuda Carmeli Journal: Clin Infect Dis Date: 2002-12-13 Impact factor: 9.079
Authors: Linda K McDougal; Christine D Steward; George E Killgore; Jasmine M Chaitram; Sigrid K McAllister; Fred C Tenover Journal: J Clin Microbiol Date: 2003-11 Impact factor: 5.948
Authors: Luisa Morales-Torres; Sharon Rodríguez; Jennifer Toro; Wanda Lledo; Carmen Ortiz; Vivian Green Journal: P R Health Sci J Date: 2015-12 Impact factor: 0.705
Authors: David K Warren; Martin Prager; Satish Munigala; Meghan A Wallace; Colleen R Kennedy; Kerry M Bommarito; John E Mazuski; Carey-Ann D Burnham Journal: Infect Control Hosp Epidemiol Date: 2016-02-02 Impact factor: 3.254
Authors: Hatice Karauzum; Arundhathi Venkatasubramaniam; Rajan P Adhikari; Tom Kort; Frederick W Holtsberg; Ipsita Mukherjee; Mark Mednikov; Roger Ortines; Nhu T Q Nguyen; Thien M N Doan; Binh An Diep; Jean C Lee; M Javad Aman Journal: Front Immunol Date: 2021-03-10 Impact factor: 7.561